A Study of CFTR modulator combination therapy for people Heterozygous for the F508del Mutation and a Minimal Function Mutation (VX-659)

Details

Therapeutic category
Restore CFTR Function
Trial status
closed Participating Centres
Phase
Phase III

Full title

A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

A Phase 3, Randomised, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Trial Reference Number
105982
Trial type
Medication
Length of participation
24 weeks
Recruitment target
360
Last edited date
17/10/2019
CF sponsor
Vertex Pharmaceuticals Incorporated
CF sponsor type
Commercial

Who can take part?

Top inclusion criteria
  • Age 12 years or older
  • Heterozygous for F508del and a minimal function mutation
  • FEV1 value ≥40% and ≤90% of predicted mean for age, sex, and height

Your donation will make a difference:

Select amount